TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 18,400 shares, a decline of 91.5% from the November 15th total of 215,500 shares. Based on an average trading volume of 47,900 shares, the days-to-cover ratio is presently 0.4 days. Approximately 2.7% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $99.00 price target on shares of TransCode Therapeutics in a research report on Friday, November 15th.

TransCode Therapeutics Price Performance

Shares of RNAZ stock traded down $0.56 during mid-day trading on Wednesday, reaching $7.89. The stock had a trading volume of 10,507 shares, compared to its average volume of 37,420. TransCode Therapeutics has a one year low of $7.13 and a one year high of $277.20. The firm’s 50 day simple moving average is $481.63 and its 200 day simple moving average is $639.30.

Institutional Investors Weigh In On TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management boosted its holdings in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,138 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.